reports
- Fabrice Farigoule
Integrating the FY24 numbers. (Crossject)
Integrating the FY24 numbers. EPS CHANGE CHANGE IN EPS 2024 : € (0.30) vs (0.23) ns 2025 : € 0.00 vs 0.02 ns We have integrated the set of FY24 numbers released yesterday. The FY24 net loss came in higher than our forecast, mainly owing to higher financial expenses (bond issuance to HCM) and a lower tax credit. This does not change our forecasts and view looking forward, based on the launch of Zepizure. CHANGE IN DCF € 6.97 vs 7.51 -7.23% Our DCF valuation has reset lower owing to a highe...
- Andreas Riemann
- Jean Danjou
- Marc Lavaud
- Youssef Besbes
ZIL2 ELRINGKLINGER AG
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
CGM CEGEDIM SA
BOSS HUGO BOSS AG
NANO NANOBIOTIX SA
SESL SES-IMAGOTAG SA
XIL XILAM ANIMATION SA
ALR ALIOR BANK SA
JUN3 JUNGHEINRICH AG PREF
DMP DERMAPHARM HOLDING SE
TGN SOCIETATEA NATIONALA DE TRANSPORT GAZE NATURALE TRANSGAZ S.A.
VOS VOSSLOH AG
2CRSI 2CRSI SA
GRE GRENERGY RENOVABLES
CLA CLARANOVA SE
SFQ SAF-HOLLAND SE
MRX MISTER SPEX SE
ENER GRUPO ECOENER S.A.
LOUP SOCIETE L.D.C.
- Andreas Riemann
- Jean Danjou
- Marc Lavaud
- Youssef Besbes
ZIL2 ELRINGKLINGER AG
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
HCO HIGHCO SA
CGM CEGEDIM SA
BOSS HUGO BOSS AG
NANO NANOBIOTIX SA
SESL SES-IMAGOTAG SA
XIL XILAM ANIMATION SA
ALR ALIOR BANK SA
JUN3 JUNGHEINRICH AG PREF
DMP DERMAPHARM HOLDING SE
TGN SOCIETATEA NATIONALA DE TRANSPORT GAZE NATURALE TRANSGAZ S.A.
VOS VOSSLOH AG
2CRSI 2CRSI SA
GRE GRENERGY RENOVABLES
CLA CLARANOVA SE
SFQ SAF-HOLLAND SE
MRX MISTER SPEX SE
ENER GRUPO ECOENER S.A.
LOUP SOCIETE L.D.C.
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
- Fabrice Farigoule
FY24 and outlook: long is the road…
FY24 and outlook: long is the road… EARNINGS/SALES RELEASES The group has released its FY24 results. The figures are not particularly meaningful, as they pertain to products still under development. However, we recognise that financing needs remain a concern. The expected EUA filing in Q225 is confirmed, which is positive. Nonetheless, the immediate requirement for additional funding is evident. FACT The group released its FY24 results. Operating income was €13.256m compared to €13.326m in t...
CROSSJECT reports financial results for 2024
CROSSJECT reports financial results for 2024 Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer USA.Visibility gained on pipeline programs developed in collaboration with Eton Pharmaceuticals, Inc (Eton).Cash position increasing significantly to 7 million euros as of December 31, 2024. Dijon, France, March 27, 2025 (07.30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ) a specialty pharmaceutical company in late-stage development a...
CROSSJECT publie ses résultats financiers pour 2024
CROSSJECT publie ses résultats financiers pour 2024 Communiqué de presse CROSSJECT publie ses résultats financiers pour 2024 Continuité dans la production satisfaisante de lots règlementaires en vue d’un dépôt de dossier en T2 2025.Recrutement de Tony Tipton aux Etats-Unis comme Directeur Opérationnel US.Gain de visibilité sur les programmes en collaboration avec Eton Pharmaceuticals, Inc. (Eton) du pipeline.Une position de trésorerie en forte hausse à 7 millions d’euros au 31 décembre 2024. Dijon, France, 27 mars 2025 (07.30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ) socié...
CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS...
CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale Communiqué de presse CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale CROSSJECT a renforcé sa collaboration avec ETON PHARMACEUTICALS, Inc. (« ETON ») en mettant à disposition sa formulation innovante d'hydrocortisone (la « formulation CROSSJECT ») pour conquérir le marché hospitalier de l'insuffisance surrénale...
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc....
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals, Inc. (“Eton”) by providing its proprietary innovative hydrocortisone formulation (the “CROSSJECT Formulation”) to enter the hospital adrenal insufficiency market. CROSSJECT will earn a high-single digit royalty on ETON’s net sales. ETON confirmed its commitment to finalize the dev...
CROSSJECT achieves key ZEPIZURE® manufacturing batch stability milesto...
CROSSJECT achieves key ZEPIZURE® manufacturing batch stability milestones Press Release CROSSJECT achieves key ZEPIZURE® manufacturing batch stability milestones Satisfactory 6-month room temperature stability results for the Registration Batch of ZEPIZURE®;CDMO Partner EUROFINS in the process of producing additional validation batches as part of regulatory application;Manufacturing progress supports timelines toward filing of Emergency Use Authorization application by BARDA. Dijon, France March 18, 2025 CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company...
CROSSJECT franchit une étape clé dans la stabilité des lots produits d...
CROSSJECT franchit une étape clé dans la stabilité des lots produits de ZEPIZURE® Communiqué de presse CROSSJECT franchit une étape clé dans la stabilité des lots produits de ZEPIZURE® Résultats satisfaisants de stabilité à 6 mois à température ambiante pour le lot d'enregistrement de ZEPIZURE® ;Le partenaire CDMO EUROFINS est en train de produire des lots de validation supplémentaires dans le cadre de la soumission du dossier réglementaire;Les avancées en matière de production soutiennent le calendrier de dépôt de la demande d'autorisation en utilisation d'urgence par la BARDA. Di...
Crossject : Information relative au nombre total de droits de vote et ...
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 10 mars 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composant son...
Crossject : Information relative au nombre total de droits de vote et ...
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 10 mars 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composant son ...
Crossject announces the reappointment of Patrick Alexandre and Isabell...
Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board Dijon, FRANCE, February 12, 2025 – 0730 (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces that, as of February 17, its Executive Board will be made up of Patrick Alexandre, Chairman, and Isabelle Liebschutz, Quality and Regulatory Affairs Director and the Compa...
- Fabrice Farigoule
A complex financing given the amounts involved
A complex financing given the amounts involved FINANCING ISSUE The group announced the issuance of a second tranche of bonds to Heights Capital, related to the February 2024 issuance, and amended the bond conditions. Overall, this will not significantly impact our figures, as the additional dilution is at least partially or fully offset by the cash inflow. FACT Crossject announced the issuance to Heights of a second tranche with a nominal value of €2,496,400, at an issue price of 90% of the...
COMPLETION OF THE TRANSACTIONS ANNOUNCED IN DECEMBER 2024 RELATING TO ...
COMPLETION OF THE TRANSACTIONS ANNOUNCED IN DECEMBER 2024 RELATING TO THE AMENDMENT OF THE CONVERTIBLE BONDS SUBSCRIBED BY AN ENTITY AFFILIATED TO HEIGHTS CAPITAL MANAGEMENT, INC. (“HEIGHTS”) AND THE ISSUE OF A SECOND ASSIMILABLE TRANCHE Press ReleaseDijon, FRANCE, February 6, 2025 –0730h (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces, in accordance with the agreement entered into with...
Réalisation des opérations annoncées en décembre 2024 relatives a la m...
Réalisation des opérations annoncées en décembre 2024 relatives a la modification des obligations convertibles souscrites par une entité affiliée à Heights Capital Management, Inc. (« Heights ») et l’émission d’une seconde tranche assimilab Communiqué de Presse Dijon, FRANCE, 6 février 2025 – 0730 (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), société pharmaceutique spécialisée dans le développement des médicaments exploitant son auto-injecteur sans aiguilles ZENEO®, une technologie unique et récompensée qui permet d’administrer des médicaments vitaux dans des situations d...
Crossject : Information relative au nombre total de droits de vote et ...
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 15 janvier 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composant ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.